For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231106:nRSF2564Sa&default-theme=true
RNS Number : 2564S Cambridge Nutritional Sciences PLC 06 November 2023
Cambridge Nutritional Sciences plc
(the 'Company' or 'CNS')
Notice of Results and Investor Presentation
Cambridge Nutritional Sciences plc (AIM: CNSL), the specialist medical
diagnostics company focused on promoting a personalised and functional
approach to health and nutrition, confirms it will issue its Half Year
results for the six months ended 30 September 2023 on Thursday 23 November
2023.
Investor presentation
Jag Grewal, CEO and Simon Douglas, Chairman will provide a live presentation
relating to the Half Year Results via the Investor Meet Company platform
on Thursday 23 November 2023 at 16:30 BST.
The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to
meet Cambridge Nutritional Sciences plc via:
https://www.investormeetcompany.com/cambridge-nutritional-sciences-plc/register-investor
(https://www.investormeetcompany.com/cambridge-nutritional-sciences-plc/register-investor)
Investors who already follow Cambridge Nutritional Sciences plc on the
Investor Meet Company platform will automatically be invited.
Contacts:
Cambridge Nutritional Sciences plc www.cnsplc.com (http://www.cnsplc.com)
Jag Grewal, Chief Executive Officer via Walbrook PR
Cavendish Capital Markets Limited Tel: 020 7220 0500
Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or CNS@walbrookpr.com (mailto:CNS@walbrookpr.com)
Paul McManus / Sam Allen Mob: 07980 541 893 / 07502 558 258
About Cambridge Nutritional Sciences plc
Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical
diagnostics company focused on industry-leading Health and Nutrition products.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NORFSAFWEEDSEIF